Although other companies are poised to have GLP-1 receptor agonist drugs for weight loss approved, they are not likely to make much of a dent in the dominance of Eli Lilly (NYSE:LLY) and Novo Nordisk ...
Source Linkseekingalpha08-26
Although other companies are poised to have GLP-1 receptor agonist drugs for weight loss approved, they are not likely to make much of a dent in the dominance of Eli Lilly (NYSE:LLY) and Novo Nordisk ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email:uservice@ttm.financial